What's behind Novo Nordisk's latest 2.1% stock surge?
Novo Nordisk A/S (NVO) advanced 2.1% after raising its 2026 sales and profit outlook, driven by stronger-than-expected demand for obesity treatments and continued momentum in the Wegovy pill. The move is supported by short- and medium-term upward momentum, with NVO trading above its 20-day and 50-day moving averages but limited by resistance at $42.8 and a longer-term bearish alignment below the 200-day average.
Highlights
- Novo Nordisk reported third-quarter adjusted sales growth of 4% to DKK 79.2 billion with strong demand for obesity treatments and over 5 million Wegovy pill prescriptions.
- The company increased its 2026 sales and profit guidance and maintained a 4.4% dividend yield with a 33% payout ratio.
- Shares of Novo Nordisk trade with short- and medium-term upward momentum, but are capped by resistance at $42.8 with an expected range of $39.5 to $42.8.
Upgraded guidance and buybacks as volume strategy reshapes business
Novo Nordisk launched a DKK 15 billion share repurchase programme on May 6, 2026, and as of November 9, 2026, had bought back 42.6 million B shares for DKK 11.8 billion, increasing its treasury holdings to 56.6 million B shares. The company reported third-quarter 2026 adjusted sales growth of 4% to DKK 79.2 billion, with notable demand for obesity treatments and the Wegovy pill surpassing 5 million prescriptions. Following these results, Novo Nordisk upgraded its 2026 sales and profit guidance and maintained a 4.4% dividend yield with a 33% payout ratio. The company continues to transition to a volume-driven business model, emphasizing disease prevention, treatment access, and sustainability.
Upward momentum persists as technical resistance limits further gains
Novo Nordisk is trading above both its 20-day and 50-day moving averages ($39.34 and $40.58), while remaining below the 200-day moving average at $43.7. This reflects near- and medium-term upward momentum, though the longer-term picture remains bearish due to the negative alignment between the 50-day and 200-day averages. Key levels are $42.8 as the immediate resistance ceiling and $40.58 as the nearest support floor. Momentum indicators such as MACD, ADX, RSI, Stochastic RSI, and CCI are all in neutral zones, with no extremes present. Bull/Bear Power is positive, showing intraday buyer strength, while the Awesome Oscillator also indicates a prevailing upward bias. Intraday tone is firm, with the current price near the daily high and volatility at 1.88%.
Earlier, analysts noted that Novo Nordisk's robust business momentum was tempered by ongoing technical resistance and prevailing seller control. The current analysis highlights a more balanced market environment, with near-term upward momentum but sustained longer-term bearish risks, making $42.8 and $40.58 critical swing levels for traders to monitor in the days ahead.